When Dropbox wanted to advertise their product, "Dropbox Paper," they were looking to tap into the young creatives market. Dropbox turned to The California Sunday Magazine, but instead of taking out an ad in their paper, Dropbox went a more creative route by creating an ad that illustrates the process of using Dropbox Paper.
Dropbox Paper teamed up with the weekend magazine to show how creatives can collaborate from all corners of the world through the cloud. The project resulted in three unique films, created by 25 individuals, across 3 continents, and 6 different time zones. These team members never met, but were still able to create together.
Chas Edwards, President and Publisher of The California Sunday Magazine, joins Cheddar to explain how this initiative is an illustration of where the advertising world is going. Consumers don't want to be served ads, they want to consume more content.
Conditions have been mostly nice for travelers flying ahead of and on Christmas Day, but some naughty disruptions plagued those flying with Southwest Airlines again this year.
Gift cards make great stocking stuffers — just as long as you don't stuff them in a drawer and forget about them after the holidays.
Big Business This Week is a guided tour through the biggest market stories of the week, from winning stocks to brutal dips to the facts and forecasts generating buzz on Wall Street.
Bristol Myers Squibb agreed to buy schizophrenia drug maker Karuna Therapeutics in a $14 billion deal.
Supermarket chain Ralphs is facing a new lawsuit from the state of California.
Shake Shack is giving out free fried chicken sandwiches, bacon cheese fries and milkshakes nationwide.
The IRS is announcing a voluntary disclosure program.
Lionsgate announced its studio division is going to spin off in a merger with Screaming Eagle Acquisition Corp., which is a special purpose acquisition company.
A new report suggests that it's getting more difficult for an average American to afford a home.
The Food and Drug Administration warned consumers about a copycat version of the diabetes drug Ozempic.
